Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Annual Report to the Food and Drug Administration on Didemnin B (NSC-3253219, IND-245055), August 1996

  2. Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of Didemnin B, a cyclic depsipeptide. J Cancer Clin Oncol 24: 1699–1706, 1988

    Article  Google Scholar 

  3. Stewart JA, Low JB, Roberts JD, Blow A: A phase I clinical trial of Didemnin B. Cancer 68: 2550–2554, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Kansas Medical Center, Kansas City, KS

    Sarah A. Taylor

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Dorothy J. Giroux

  3. University of Utah Medical Center, Salt Lake City, UT

    Kurt A. Jaeckle

  4. Thompson Cancer Survival Center, Knoxville, TN

    Timothy J. Panella

  5. Wichita CCOP, Wichita, KS

    Shaker R. Dakhil

  6. University of Texas Southwestern, Dallas, TX, USA

    S. Clifford Schold

Authors
  1. Sarah A. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorothy J. Giroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kurt A. Jaeckle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy J. Panella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaker R. Dakhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Clifford Schold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, S.A., Giroux, D.J., Jaeckle, K.A. et al. Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study. Invest New Drugs 16, 331–332 (1998). https://doi.org/10.1023/A:1006273214056

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006273214056

Search

Navigation